ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
04 Janvier 2018 - 7:00AM
YASTEST
GHENT, Belgium, 4 January 2018 -
Ablynx [Euronext Brussels and Nasdaq: ABLX]
today announced that it will present at the 36
th Annual
J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30
a.m. Pacific Standard Time (06:30 p.m. Central European Time).
The presentation will be hosted by
Dr Edwin Moses, CEO of Ablynx, and will be followed by a Q&A
break-out session. The presentation will provide an overview of the
major achievements in 2017 as well as an update on the Company's
proprietary key clinical assets, its partnered programmes and the
outlook for 2018. During this conference, Ablynx will also hold
one-on-one meetings with institutional investors.
The presentation will be webcast
live and can be accessed on the day via this link. The presentation
will be available on the Company's website, under the News &
Events section for 90 days following the event.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024